Welcome to our dedicated page for Tango Therapeutics news (Ticker: TNGX), a resource for investors and traders seeking the latest updates and insights on Tango Therapeutics stock.
Tango Therapeutics, Inc. (TNGX) is a clinical-stage biotechnology company pioneering precision oncology solutions through innovative target discovery and therapeutic development. This page provides authorized updates on their research programs, clinical trials, and strategic initiatives in cancer treatment innovation.
Investors and researchers will find verified information about TNGX's pipeline progress, including PRMT5 inhibitor developments for CNS/non-CNS cancers and discontinued programs like TNG348. All content undergoes strict verification to ensure accuracy in reporting scientific milestones and regulatory updates.
Key coverage areas include clinical trial phases, research collaborations, peer-reviewed study publications, and corporate developments. The resource is particularly valuable for tracking therapies addressing tumor suppressor gene restoration and immune evasion mechanisms.
Bookmark this page for real-time updates on Tango Therapeutics' work in CRISPR-enabled drug discovery and their mission to transform cancer treatment paradigms through precision medicine approaches.
Tango Therapeutics (NASDAQ: TNGX) showcased key findings from its precision oncology portfolio at the AACR 2023 Annual Meeting in Orlando, Florida. Presentations included promising preclinical data for TNG908, a PRMT5 inhibitor targeting glioblastoma, which is currently in a phase 1/2 clinical trial. Additionally, TNG260 showed potential in reversing immune evasion in STK11-mutant cancers and will enter clinical trials later in 2023. The company also highlighted TNG462, another promising PRMT5 inhibitor, and TNG348, a selective USP1 inhibitor for BRCA1/2 mutant cancers, with IND submissions planned. These developments underscore Tango's commitment to targeting critical cancer pathways.
Tango Therapeutics (NASDAQ: TNGX) has received FDA clearance for its IND application for TNG260, a first-in-class inhibitor targeting the CoREST complex, aimed at treating STK11-mutant cancers. This milestone enables the initiation of a Phase 1/2 clinical trial expected in the second half of 2023. STK11 mutations contribute to resistance against standard immunotherapies in cancers such as non-small cell lung cancer. The trial will assess the safety and efficacy of TNG260 in combination with pembrolizumab in patients with various solid tumors having STK11 mutations. This breakthrough underscores Tango's commitment to advancing precision cancer therapies.
Tango Therapeutics (NASDAQ: TNGX) announced key developments in its clinical pipeline and financial results for 2022. The FDA granted Fast Track Designation to TNG462, a next-generation PRMT5 inhibitor, following IND clearance in January 2023. The company initiated a clinical trial for TNG908 and expects updates on its progress in Q2 2023. Financially, Tango reported a net loss of $108.2 million for 2022, compared to $58.2 million in 2021. Collaboration revenue decreased to $24.9 million, down from $26.0 million. Research and development expenses rose to $105.9 million, reflecting increased program advancement costs. Tango ended 2022 with $366.1 million in cash, sufficient to fund operations until 2025.
Tango Therapeutics (NASDAQ: TNGX) announced the acceptance of two oral and two poster presentations at the AACR 2023 Annual Meeting from April 14-19 in Orlando, Florida. The oral presentations include TNG908, a promising PRMT5 inhibitor showing three-fold increased median survival in glioblastoma models, and TNG260, aimed at STK11-mutant cancers. The poster presentations feature TNG348, targeting BRCA1/2 mutations, and TNG462, another PRMT5 inhibitor for MTAP-deleted tumors. These findings highlight Tango's innovative approach in precision oncology and the potential for advancements in cancer treatment.
FAQ
What is the current stock price of Tango Therapeutics (TNGX)?
What is the market cap of Tango Therapeutics (TNGX)?
